Credit Suisse Ag Pmv Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$4.77 - $9.16 $23 - $45	5 Added 0.04%	14,122 $67,000
Q4 2022 Feb 13, 2023	SELL	$8.17 - $12.95 $21,642 - $34,304	-2,649 Reduced 15.8%	14,117 $122,000
Q3 2022 Nov 10, 2022	BUY	$11.4 - $17.18 $70,976 - $106,962	6,226 Added 59.07%	16,766 $199,000
Q2 2022 Aug 12, 2022	BUY	$9.23 - $22.43 $97,284 - $236,412	10,540 New	10,540 $150,000
Q1 2022 May 16, 2022	SELL	$14.86 - $23.55 $132,878 - $210,584	-8,942 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$19.99 - $30.24 $4,117 - $6,229	206 Added 2.36%	8,942 $207,000
Q3 2021 Nov 12, 2021	SELL	$26.84 - $36.58 $7,193 - $9,803	-268 Reduced 2.98%	8,736 $260,000
Q2 2021 Aug 16, 2021	BUY	$28.01 - $36.01 $252,202 - $324,234	9,004 New	9,004 $307,000
Q1 2021 May 14, 2021	SELL	$30.66 - $49.5 $123,467 - $199,336	-4,027 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$31.86 - $61.51 $128,300 - $247,700	4,027 New	4,027 $248,000

41.9M

3.1K

1.7K

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $72.5M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.